Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Multi-Ethnic Study of Atherosclerosis and Beta-Blocker Effect on Remodeling and Gene Expression Trial) - 21/12/17
, Richard A. Kronmal, PhD b, David A. Bluemke, MD, PhD c, Peter M. Buttrick, MD d, Kenneth L. Jones, PhD d, David P. Kao, MD d, Steven M. Kawut, MD, MS e, Eric V. Krieger, MD a, Joao A. Lima, MD f, g, Wayne Minobe, BS d, David D. Ralph, MD a, Ryan J. Tedford, MD h, Noel S. Weiss, MD, DrPH i, Michael R. Bristow, MD, PhD dAbstract |
Myocardial H2 receptor activation contributes to heart failure (HF) in preclinical models, and H2 receptor antagonists are associated with decreased HF incidence. This study evaluated whether H2 histamine receptor (HRH2) single nucleotide polymorphisms (SNPs) are associated with HF incidence and whether myocardial transcript abundance is associated with HF recovery. The association of SNPs in HRH2 with incident HF was characterized using Cox proportional hazards regression among participants in the Multi-Ethnic Study of Atherosclerosis. Differences in myocardial HRH2 transcripts were characterized in participants with dilated cardiomyopathy comparing 6 “super-responders” with 6 nonresponders to β blockade in the Beta-Blocker Effect on Remodeling and Gene Expression Trial. In MESA, no candidate SNP was associated with HF in black, Hispanic, or white participants. The rs2241562 minor allele was present only in Chinese participants and the adjusted HF hazard among those with 1 or more copies of this allele was 3.7, 95% confidence interval 1.0 to 13.4. In BORG, super-responders to β blockade had higher levels of myocardial HRH2 transcript at baseline compared with nonresponders (fragments per kilobase per transcript per million mapped reads: Variant 2, 5.5 ± 1.1 compared with 3.2 ± 0.8 in nonresponders, p = 0.002; Variant 1 + 2, 32.1 ± 7.4 compared with 23.3 ± 4.2 in nonresponders, p = 0.04). In conclusion, the presence of a minor allele at rs2241562 was associated with increased HF incidence in Chinese participants. Differences in myocardial HRH2 transcript abundance were seen in participants with dilated cardiomyopathy who responded to β blockade. These observations support the hypothesis that HRH2 is involved in the pathogenesis of HF.
Le texte complet de cet article est disponible en PDF.Plan
| The Multi-Ethnic Study of Atherosclerosis (MESA) and the MESA SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI, Bethesda, Maryland) in collaboration with MESA Investigators. Support for MESA is provided by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420, UL1-TR-001881, and DK063491. Funding for CARe genotyping was provided by NHLBI Contract N01-HC-65226. The Beta-Blocker Effect on Remodeling and Gene Expression Trial and associated research in this manuscript was supported by the NHLBI (2R01 HL48013, 3R01 HL48013, R01 HL71118, T32 HL007822, and L30 HL110124) and research grants from GlaxoSmithKline (Philadelphia, Pennsylvania) and AstraZeneca (Wilmington, Delaware). This publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (Bethesda, Maryland) under Award KL2TR000421. |
|
| See page 261 for disclosure information. |
Vol 121 - N° 2
P. 256-261 - janvier 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
